Elisa Dorantes-Acosta1, Diana Ávila-Montiel2, Miguel Klünder-Klünder2, Luis Juárez-Villegas3, Horacio Márquez-González4,5. 1. Biobanco de Investigación en Células Leucémicas, Hospital Infantil de México Federico Gómez, México City, Mexico. 2. Subdirección de Investigación, Hospital Infantil de México Federico Gómez, México City, Mexico. 3. Departamento de Onco-Hematología, Hospital Infantil de México Federico Gómez, México City, Mexico. 4. Investigación Clínica, Hospital Infantil de México Federico Gómez, México City, Mexico. 5. Cardiopatías Congénitas. Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), México City, Mexico.
Abstract
BACKGROUND: The pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected all age groups, including the pediatric population, in 3-5% of all cases. We performed a meta-analysis to understand the survival and associated complications in pediatric cancer patients as well as their hospitalization, intensive care, and ventilation care (supplemental oxygen/endotracheal intubation) needs. METHODS: A systematic search was performed using MEDLINE, TRIP Database, International Clinical Trials Registry Platform (WHO), The Cochrane Library, Wiley, LILACS, and Google Scholar. Additionally, a search using the snowball method was performed in Nature, New England Journal of Medicine, Science, JAMA, ELSEVIER editorial, Oxford University Press, The Lancet, and MedRxiv. Searches were conducted until July 18, 2020. A total of 191 cancer patients with coronavirus disease 2019 (COVID-19) were integrated from 15 eligible studies. In a sub-analysis, patients were stratified into two groups: hematological cancer and solid tumors. Outcome measures were overall survival, risk of hospitalized or needing intensive care, and need for ventilatory support in any modality. The random effects statistical analysis was performed with Cochran's chi square test. The odds ratio (OR) and heterogeneity were calculated using the I2 test. RESULTS: The overall survival was 99.4%. There were no statistically significant differences in the risk of hospitalization between hematological malignancies and solid tumors (95% confidence interval [CI] 0.48-18.3; OR = 2.94). The risk of being admitted to the intensive care unit was also not different between hematological malignancies and other tumors (95% CI 0.35-5.81; OR = 1.42). No differences were found for the need of ventilatory support (95% CI 0.14-3.35; OR = 0.68). Although all the studies were cross-sectional, the mortality of these patients was 0.6% at the time of analysis. CONCLUSIONS: In the analyzed literature, survival in the studied group of patients with COVID-19 was very high. Suffering from hematological neoplasia or other solid tumors and COVID-19 was not a risk factor in children with cancer for the analyzed outcomes.
BACKGROUND: The pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected all age groups, including the pediatric population, in 3-5% of all cases. We performed a meta-analysis to understand the survival and associated complications in pediatric cancer patients as well as their hospitalization, intensive care, and ventilation care (supplemental oxygen/endotracheal intubation) needs. METHODS: A systematic search was performed using MEDLINE, TRIP Database, International Clinical Trials Registry Platform (WHO), The Cochrane Library, Wiley, LILACS, and Google Scholar. Additionally, a search using the snowball method was performed in Nature, New England Journal of Medicine, Science, JAMA, ELSEVIER editorial, Oxford University Press, The Lancet, and MedRxiv. Searches were conducted until July 18, 2020. A total of 191 cancer patients with coronavirus disease 2019 (COVID-19) were integrated from 15 eligible studies. In a sub-analysis, patients were stratified into two groups: hematological cancer and solid tumors. Outcome measures were overall survival, risk of hospitalized or needing intensive care, and need for ventilatory support in any modality. The random effects statistical analysis was performed with Cochran's chi square test. The odds ratio (OR) and heterogeneity were calculated using the I2 test. RESULTS: The overall survival was 99.4%. There were no statistically significant differences in the risk of hospitalization between hematological malignancies and solid tumors (95% confidence interval [CI] 0.48-18.3; OR = 2.94). The risk of being admitted to the intensive care unit was also not different between hematological malignancies and other tumors (95% CI 0.35-5.81; OR = 1.42). No differences were found for the need of ventilatory support (95% CI 0.14-3.35; OR = 0.68). Although all the studies were cross-sectional, the mortality of these patients was 0.6% at the time of analysis. CONCLUSIONS: In the analyzed literature, survival in the studied group of patients with COVID-19 was very high. Suffering from hematological neoplasia or other solid tumors and COVID-19 was not a risk factor in children with cancer for the analyzed outcomes.
Authors: Philip Zachariah; Candace L Johnson; Katia C Halabi; Danielle Ahn; Anita I Sen; Avital Fischer; Sumeet L Banker; Mirna Giordano; Christina S Manice; Rebekah Diamond; Taylor B Sewell; Adam J Schweickert; John R Babineau; R Colin Carter; Daniel B Fenster; Jordan S Orange; Teresa A McCann; Steven G Kernie; Lisa Saiman Journal: JAMA Pediatr Date: 2020-10-05 Impact factor: 16.193
Authors: Jenna Rossoff; Ami B Patel; Emily Muscat; Larry K Kociolek; William J Muller Journal: Pediatr Blood Cancer Date: 2020-06-23 Impact factor: 3.838
Authors: Elizabeth Barnett Pathak; Jason L Salemi; Natasha Sobers; Janelle Menard; Ian R Hambleton Journal: J Public Health Manag Pract Date: 2020 Jul/Aug
Authors: Amna Majeed; Tom Wright; Biqi Guo; Ramandeep S Arora; Catherine G Lam; Alexandra L Martiniuk Journal: Front Oncol Date: 2022-04-07 Impact factor: 5.738